Free Trial
→ The 1934 playbook (From American Alternative) (Ad)tc pixel Free NRSNW Stock Alerts

NeuroSense Therapeutics (NRSNW) Competitors

$0.15 +0.01 (+4.07%)
As of 10:15 AM Eastern
This is a fair market value price provided by Massive. Learn more.
Compare

NRSNW vs. AIMDW, ALVOW, ARAV, ACABW, and BFRIW

Should you buy NeuroSense Therapeutics stock or one of its competitors? MarketBeat compares NeuroSense Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with NeuroSense Therapeutics include Ainos (AIMDW), Alvotech (ALVOW), Aravive (ARAV), Atlantic Coastal Acquisition Corp. II (ACABW), and Biofrontera (BFRIW). These companies are all part of the "pharmaceutical products" industry.

How does NeuroSense Therapeutics compare to Ainos?

NeuroSense Therapeutics (NASDAQ:NRSNW) and Ainos (NASDAQ:AIMDW) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, risk, profitability, media sentiment, valuation, analyst recommendations, dividends and institutional ownership.

Company Net Margins Return on Equity Return on Assets
NeuroSense TherapeuticsN/A N/A N/A
Ainos N/A N/A N/A

In the previous week, Ainos had 1 more articles in the media than NeuroSense Therapeutics. MarketBeat recorded 2 mentions for Ainos and 1 mentions for NeuroSense Therapeutics. NeuroSense Therapeutics' average media sentiment score of 1.89 beat Ainos' score of 0.93 indicating that NeuroSense Therapeutics is being referred to more favorably in the media.

Company Overall Sentiment
NeuroSense Therapeutics Very Positive
Ainos Positive

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NeuroSense TherapeuticsN/AN/AN/AN/AN/A
Ainos$18.11KN/AN/AN/AN/A

Summary

Ainos beats NeuroSense Therapeutics on 2 of the 3 factors compared between the two stocks.

How does NeuroSense Therapeutics compare to Alvotech?

NeuroSense Therapeutics (NASDAQ:NRSNW) and Alvotech (NASDAQ:ALVOW) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, dividends, risk, institutional ownership, earnings, media sentiment, analyst recommendations and profitability.

Company Net Margins Return on Equity Return on Assets
NeuroSense TherapeuticsN/A N/A N/A
Alvotech N/A N/A N/A

In the previous week, NeuroSense Therapeutics and NeuroSense Therapeutics both had 1 articles in the media. NeuroSense Therapeutics' average media sentiment score of 1.89 equaled Alvotech'saverage media sentiment score.

Company Overall Sentiment
NeuroSense Therapeutics Very Positive
Alvotech Very Positive

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NeuroSense TherapeuticsN/AN/AN/AN/AN/A
Alvotech$586.32MN/AN/AN/AN/A

Summary

Alvotech beats NeuroSense Therapeutics on 1 of the 1 factors compared between the two stocks.

How does NeuroSense Therapeutics compare to Aravive?

NeuroSense Therapeutics (NASDAQ:NRSNW) and Aravive (NASDAQ:ARAV) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, analyst recommendations, media sentiment, earnings, profitability, institutional ownership, dividends and valuation.

35.8% of Aravive shares are held by institutional investors. 60.4% of Aravive shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NeuroSense TherapeuticsN/AN/AN/AN/AN/A
AraviveN/AN/AN/A-$0.90N/A

Company Net Margins Return on Equity Return on Assets
NeuroSense TherapeuticsN/A N/A N/A
Aravive N/A N/A N/A

In the previous week, NeuroSense Therapeutics had 1 more articles in the media than Aravive. MarketBeat recorded 1 mentions for NeuroSense Therapeutics and 0 mentions for Aravive. NeuroSense Therapeutics' average media sentiment score of 1.89 beat Aravive's score of 0.00 indicating that NeuroSense Therapeutics is being referred to more favorably in the media.

Company Overall Sentiment
NeuroSense Therapeutics Very Positive
Aravive Neutral

Summary

NeuroSense Therapeutics and Aravive tied by winning 2 of the 4 factors compared between the two stocks.

How does NeuroSense Therapeutics compare to Atlantic Coastal Acquisition Corp. II?

Atlantic Coastal Acquisition Corp. II (NASDAQ:ACABW) and NeuroSense Therapeutics (NASDAQ:NRSNW) are both pharmaceutical products companies, but which is the better investment? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, valuation, dividends, profitability, earnings, institutional ownership and risk.

In the previous week, NeuroSense Therapeutics had 1 more articles in the media than Atlantic Coastal Acquisition Corp. II. MarketBeat recorded 1 mentions for NeuroSense Therapeutics and 0 mentions for Atlantic Coastal Acquisition Corp. II. NeuroSense Therapeutics' average media sentiment score of 1.89 beat Atlantic Coastal Acquisition Corp. II's score of 0.00 indicating that NeuroSense Therapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
Atlantic Coastal Acquisition Corp. II Neutral
NeuroSense Therapeutics Very Positive

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Atlantic Coastal Acquisition Corp. IIN/AN/AN/AN/AN/A
NeuroSense TherapeuticsN/AN/AN/AN/AN/A

Company Net Margins Return on Equity Return on Assets
Atlantic Coastal Acquisition Corp. IIN/A N/A N/A
NeuroSense Therapeutics N/A N/A N/A

Summary

NeuroSense Therapeutics beats Atlantic Coastal Acquisition Corp. II on 2 of the 2 factors compared between the two stocks.

How does NeuroSense Therapeutics compare to Biofrontera?

Biofrontera (NASDAQ:BFRIW) and NeuroSense Therapeutics (NASDAQ:NRSNW) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their media sentiment, valuation, analyst recommendations, profitability, risk, earnings, dividends and institutional ownership.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Biofrontera$43.20MN/AN/AN/AN/A
NeuroSense TherapeuticsN/AN/AN/AN/AN/A

In the previous week, Biofrontera and Biofrontera both had 1 articles in the media. NeuroSense Therapeutics' average media sentiment score of 1.89 beat Biofrontera's score of 1.87 indicating that NeuroSense Therapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
Biofrontera Very Positive
NeuroSense Therapeutics Very Positive

Company Net Margins Return on Equity Return on Assets
BiofronteraN/A N/A N/A
NeuroSense Therapeutics N/A N/A N/A

Summary

Biofrontera and NeuroSense Therapeutics tied by winning 1 of the 2 factors compared between the two stocks.

Get NeuroSense Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for NRSNW and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NRSNW and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

NRSNW vs. The Competition

Export
MetricNeuroSense TherapeuticsBiotechnology IndustryMedical SectorNASDAQ Exchange
Market CapN/A$429.91M$6.47B$11.77B
Dividend YieldN/A3.86%2.67%5.61%
P/E RatioN/A3.1824.5723.81
Price / SalesN/A6,477.34479.7984.86
Price / CashN/A13.1343.0554.72
Price / BookN/A83.8110.276.75
Net IncomeN/A-$96.07M$3.56B$337.26M
7 Day Performance-39.60%-0.56%-2.66%-1.98%
1 Month Performance50.25%1.20%-0.06%0.86%
1 Year Performance-71.78%47.66%20.67%24.53%

NeuroSense Therapeutics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
NRSNW
NeuroSense Therapeutics
N/A$0.15
+4.1%		N/A-61.3%$0.00N/AN/A10
AIMDW
Ainos
N/A$0.12
-8.2%		N/A+16.6%$0.00$18.11KN/A40
ALVOW
Alvotech
N/A$0.23
flat		N/A-91.9%$0.00$586.32MN/A4
ARAV
Aravive
N/A$0.04
flat		N/AN/A$0.00N/AN/A20
ACABW
Atlantic Coastal Acquisition Corp. II
N/A$0.00
flat		N/AN/A$0.00N/AN/A15

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:NRSNW) was last updated on 6/11/2026 by MarketBeat.com Staff.
From Our Partners
The 1934 playbook
In 1934, a legal government maneuver transferred billions in wealth overnight. Most Americans never saw it com...
American Alternative | Sponsoredtc pixel
June 12: $100 Turns Into $100,000?
The SpaceX IPO is scheduled for June 12, and former tech executive Jeff Brown - who identified Bitcoin, Tesla,...
Brownstone Research | Sponsoredtc pixel
$30 stock to buy before Starlink goes public (WATCH NOW!)
In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...
Paradigm Press | Sponsoredtc pixel
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Your book attached
Your Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...
Profits Run | Sponsoredtc pixel
SpaceX just filed. The clock is ticking.
Reuters reports Elon Musk filed secretly. Barron's says it's being finalized behind closed doors. CNBC just re...
The Oxford Club | Sponsoredtc pixel
Why this tiny stock may move before the SpaceX IPO drops
The projected SpaceX and xAI S-1 filing hits the SEC on June 1st - and analyst Dylan Jovine says $1.75 trillio...
Behind the Markets | Sponsoredtc pixel